You are here

Home » Content

KRONİK HEMODİYALİZ HASTALARINDA HEMODİYALİZ YETERLİLİĞİNİN HOMOSİSTEİN DÜZEYLERİNE ETKİSİ

THE EFFECT OF ADEQUATE HEMODIALYSIS ON HOMOCYSTEINE LEVELS IN PATIENTS WITH CHRONIC RENAL FAILURE

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2001

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Background: Hyperhomocysteinaemia, which is an independent cardiovascular risk factor, is common in chronic haemodialysis (HD) patients. In chronic haemodialysis patients, the effect of dialysis adequacy on homocysteine levels is object of research. Treatment with folic acid lowers tHcy in haemodialysis patients. However, in most patients normohomocysteinaemic levels can not be provided. We studied the influence of dialysis adequacy on homocysteine levels. Material and method: Thirty patients were taken in this study. They had entered in dialysis for more than one years and also taken Bl2 and folic acid. Kt/V ratios, serum albumine, folic acid, Bl2, predialysis and postdialysis total serum homocysteine (tsHcy) were measured in-patients. Non-parametric 'Wilcoxon's rank, Spearman rank correlation and multiple linear regression' tests were used in statistically analysis. Results: tsHcy were found predialysis as 10.7+9.0 (3.55-37.7) jmol/L and postdialysis 5.3+4.29 (2.25¬23.85) jmol/L (p=0.004). Predialysis tsHcy correlated significantly with Kt/V 1.26+0.15 (0.86-1.5) and serum concentrations of albumin 3.58+0.39 (2.7-4.2) gr/dl (r=-0.621, p<0.0001, r=-0.764, p<0.0001) respectively. There was not a meaningful relation between tsHcy and serum cobalamines 637.5+181.7 (260-983) pg/ml (r=-0.3, p=0.107). In contrary tsHcy correlated significantly with serum folic acid 12.2+5.2 (3-20) ng/ml (r=-0.830, p<0.0001). In a multiple linear regression analysis, Kt/V and serum folic acid levels significantly predicted tsHcy (r=-0.387, p=0.003, r=-0,487, p=0.001). Conclusions: It was seen that there was a meaningful relation between tsHcy and Kt/V, serum concentrations of albumin and folic acid levels. In conclusion; dialysis adequacy, serum concentrations of albumin and folic acid are effective factors on tsHcv levels.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Bağımsız bir kardiyovasküler risk faktörü olan hiperhomosisteinemi kronik hemodiyaliz hastalarında yaygındır. Kronik hemodiyaliz hastalarında hemodiyaliz etkinliğinin homosistein düzeylerine etkisi araştırma konusudur. Folik asid tedavisi ile homosistein düzeyleri düşmekle birlikte bir çok hastada normal homosistein düzeyleri sağlanamaz. Biz hemodiyaliz etkinliğinin homosistein düzeylerine olan etkisini araştırdık. Materyal ve metot: Bir yıldan daha uzun süre hemodiyalize giren, Bn ve folik asid kullanmakta olan 30 hasta çalışmaya alındı. Hastalarda Kt/V oranları, serum albümin, diyaliz öncesi ve sonrası total serum homosistein (tsHcy), folik asid ve kobalamin düzeyleri ölçüldü. Nonparametrik 'Wilcoxon 's rank, Spearman rank korelasyon ve multiple linear regresyon' testleri istatistiksel analizde kullanıldı. Sonuçlar: tsHcy, diyaliz öncesi 10.7+9.0 (3.55-37.7) \moVL, diyaliz sonrası 5.3+4.29 (2.25-23.85) jmol/L bulundu (p=0.004). tsHcy ile Kt/V 1.26+0.15 (0.86-1.5), ve serum albümin düzeyleri 3.58+0.39 (2.7-4.2) g/dl arasında anlamlı ilişki vardı (r=-0.621, p<0.0001, r=-0.764, p<0.0001). tsHcy ile serum B12 vitamin düzeyleri 637.5±181.7 (260-983) pg/ml arasında anlamlı ilişki yokken (r=-0.3, p=0.107), folik asit düzeyleri 12.2+5.2 (3¬20) ng/ml ile anlamlı ilişki vardı (r=-0.830, p<0.0001). Kt/V ve serum folik asid düzeyleri tsHcy için bağımsız belirleyiciler olarak bulundu (r=-0.387, p=0.003, r=- 0,487, p=0.001)). Tartışma: tsHcy ile Kt/V, serum albümin düzeyleri ve folik asid düzeyleri arasında anlamlı ilişki görülmektedir. Sonuç olarak diyaliz yeterliliği, serum albümin ve folik asid düzeyleri tsHcy düzeyleri üzerinde etkili faktörlerdir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_357.pdf
  • 4
219-222
  • Turkish

REFERENCES

References: 

1. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocysteine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-375.
2. Keebler ME, De Souza C, Fonseca V. Diagnosis and treatment of hyperhomocysteinemia. Curr Atheroscler Rep 2001;3:54-63.
3. Graham IM, Daly LE, Refsum HM, et at. Plasma
homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-1781.
4. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A
quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing
folic acid intakes. JAMA 1995;274:1049-1057.
5. Dalery K, Lussier-Cacan S, Selhub J, Davignon J, Latour Y, Genest JJr. Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins Bi2, Bf,, pyridoxal phosphate, and folate. Am J Cardiol
1995;75:1107-1111.
6. Kaplan LN, Mamer OA, Hotter LJ. Parenteral vitamin B|2 reduces hyperhomocysteinemia in end-stage renal disease. Clin Invest Med. 2001 ;24:5-l 1..
7. Al-Ahmad A, Sarnak MJ, Salem DN, Konstam MA. Cause
and management of heart failure in patients with chronic renal disease. Semin Nephrol. 2001;21:3-12.
8. Van Tellingen A,' Grooteman MP, Bartels PC, et al. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. Kidney Int 2001 ;59:342-347.
9. Arnadottir M, Berg AL, Hegbrant J, Huitberg B. Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 1999;14:142-146.
10. Frantzen F, Faaren AL, Alfheim I, Nordhei AK. An
enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998;44:311 -316.
11. Daurgidas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J
Am Soc Nephrol 1993;4:1205-1213.
12. Guttormsen AB, Schneede J, Ueland P, Refsum H. Kinetics of total plasma homocysteine in subject with hyperhomocysteinemia due to folate or cobalamin
deficiency. Am J Clin Nutr 1996;63:194-202.
13. Sunder-Plassmann G, Winkelmayer G, Fodinger M. Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease. Expert Opin Investig Drugs. 2000;9:2637-2651.
14. Van Guldener C, Robinson K. Homocysteine and renal disease. Semin Thromb Hemost. 2000;26:313-324.
15. Henning BF, Riezler R, Tepel M, et al. Evidence of altered homocysteine metabolism in chronic renal failure. Nephron
1999;83:314-322.
222

Thank you for copying data from http://www.arastirmax.com